Send to

Choose Destination
Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Author information

Vancouver Coastal Health, Vancouver, BC, Canada.
University of British Columbia, Vancouver, BC, Canada.
Neurology Center of San Antonio, San Antonio, TX, United States.
North Central Neurology Associates, Cullman, AL, United States.
Azienda Ospedaliero Universitaria San Luigi, Orbassano, Italy.
OhioHealth Neurological Physicians, Columbus, OH, United States.
Oslo University Hospital Ullevål and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Clinical Research Center (CIC), INSERM 1434, Strasbourg University, Strasbourg, France.
Imperial College Healthcare NHS Trust, London, United Kingdom.
University of Zagreb, School of Medicine and University Medical Center, Zagreb, Croatia.
Stanford Healthcare, Palo Alto, CA, United States.
Klinik für Neurologie und Palliativmedizin, Cologne, Germany.
Clinic of Neurology with Institute of Translational Neurology, University Hospital Müenster, Müenster, Germany.
El Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Hospital Clínico San Carlos, Madrid, Spain.
Neurology Associates, Maitland, FL, United States.
Revalidatie & MS Centrum, Overpelt, Belgium.
Center of Clinical Neuroscience, University Clinic Carl Gustav Carus, Dresden, Germany.
Sanofi, Cambridge, MA, United States.
Rehabilitation & MS-Centre Overpelt, Hasselt University, Hasselt, Belgium.


Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab was maintained over 7 years in subsequent extension studies (NCT00930553; NCT02255656), in the absence of continuous treatment and with a consistent safety profile. There is an increased incidence of autoimmune events in patients treated with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and nephropathy), which imparts a need for mandatory safety monitoring for 4 years following the last treatment. The risk management strategy for alemtuzumab-treated patients includes laboratory monitoring and a comprehensive patient education and support program that enables early detection and effective management of autoimmune events, yielding optimal outcomes for MS patients. Here we provide an overview of tools and techniques that have been implemented in real-world clinical settings to reduce the burden of monitoring for both patients and healthcare providers, including customized educational materials, the use of social media, and interactive online databases for managing healthcare data. Many practices are also enhancing patient outreach efforts through coordination with specialized nursing services and ancillary caregivers. The best practice recommendations for safety monitoring described in this article, based on experiences in real-world clinical settings, may enable early detection and management of autoimmune events, and help with implementation of monitoring requirements while maximizing the benefits of alemtuzumab treatment for MS patients.


alemtuzumab; anti-CD52 monoclonal antibody; autoimmune events; best practices; disease-modifying therapy; monitoring; real-world settings; relapsing-remitting multiple sclerosis

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center